젬백스

082270KOSDAQ특수 목적용 기계 제조업

43.0 / 100

Reference Date: 2026-04-13

Financial Score9.5 / 40

News Sentiment13.5 / 25

Momentum7.0 / 20

Disclosure13.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 30.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

jemBucks operates two main business segments: an environmental pollution control division producing chemical filters and air purification systems for semiconductor and display manufacturing, and a biotech division conducting clinical trials for GV1001, a telomerase-derived peptide drug candidate for Alzheimer's disease. The environmental division accounts for 99.2% of 2024 sales with its flagship product, the Chemical Air Filter, while the biotech division focuses on developing next-generation peptide drugs based on GV1001's anti-inflammatory and neuroprotective properties.

Number of Employees

217people

Average Salary

46.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 22.894.0Point

PBR

—Industry Average 1.553.5Point

ROE

-26.29Industry Average 1.250.0Point

Well below industry avg

Debt Ratio

63.27Industry Average 7.700.0Point

8.2x industry avg (risky)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼138.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -58.7% (declining, 3yr)

Detailed News Sentiment

10 totalPositive 2Neutral 3Negative 0Average Sentiment Score 58

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 27,050Won52-week high 69,80052-week low 23,100

1-month return0.0Point

1m -30.28% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

16 totalPositive 3Neutral 12Negative 1

Neutral투자판단관련주요경영사항(임상시험결과) (진행성 핵상마비 치료제로서 GV1001의 국내 2a상(GV1001-PSP-CL2-011) 임상시험의 연장 임상시험 의 최종결과보고서(CSR) 수령)2026-04-09
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-06
Neutral주식등의대량보유상황보고서(일반)2026-04-06
Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-04-06
Negative소송등의판결ㆍ결정(일정금액이상의청구)2026-03-31